iBio IBIO Stock News

With the continued spread of the Wuhan Coronavirus, iBio Inc (NYSEAMERICAN: IBIO) is making a run for the top this morning. While the company hasn’t issued any news today, the excitement is for good reason. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Will Likely Manufacture Coronavirus Vaccine No Matter Who Develops It

As mentioned above, with the news surrounding the Wuhan Coronavirus continuing to spread through the wire, biotechnology companies that are actively working to develop a vaccine or treatment are headed for the top. iBio is one of the companies on this list.

Recently, IBIO announced that it is working with CC-Pharming Ltd. of China to develop a vaccine for the Wuhan Coronavirus. This partnership provides several strategic advantages. First and foremost, CC-Pharming is located in China, leading to immediate access to the largest patient population in this space. Not to mention, CC-Pharming has recently worked on a MERS vaccine, which is key as MERS is a strain of the coronavirus.

While all of that is well and good, the real excitement has to do with the fact that no matter who develops a vaccine first, IBIO is likely to be the company to manufacture it.

That’s because iBio is the owner of a facility known as the FastPharming Facility. Built as part of a Department of Defense program aimed at the establishment of facilities that are capable of delivering medical countermeasures in response to a disease pandemic rapidly, the FastPharming Facility can mass produce vaccines incredibly quickly.

With the spread of the Wuhan Coronavirus being so pressing, it only makes sense that whichever company develops the vaccine first will look closely at IBIO as a manufacturing partner. After all, the company owns a facility that can quickly meet the demand for this vaccine.

What This All Means

At the end of the day, this all means that iBio is well-positioned to benefit no matter how things go. The company is working on developing its own vaccine. Success would be the best case scenario. However, successful development is not necessary for the company, nor its investors to benefit.

With the FastPharming facility under its belt, IBIO is well positioned to generate revenue no matter who comes up with the vaccine first as it will likely be the primary choice for development.

What Does This Have To Do With The Run Today?

EVERYTHING!

Sure, the news that iBio is working on a vaccine for the Wuhan Coronavirus is old news at this point, and so is the fact that the company runs the FastPharming facility. Nonetheless, the coronavirus itself is not old news.

In fact, no matter if you follow CNN, Fox, The New York Times, or any other news outlet, chances are that you saw news about the outbreak today. In particular, we’re seeing further concerns that the coronavirus will lead to a global pandemic. At the same time, Trump made headlines about being upset that Americans with the coronavirus were let back into the United States.

The bottom line here is that as the coronavirus news leads to fear, we’re going to see benefit among biotechnology companies directly related to combatting the issue. With IBIO not only working on a vaccine itself, but owning the facility that the vaccine will be manufactured in, no matter who develops it, the stock is likely to benefit greatly ahead.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.